Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published Date September 2008 Volume 2008:4(4) Pages 821—826

DOI http://dx.doi.org/10.2147/TCRM.S3075

Published 1 September 2008

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Thought–shape fusion and body image in eating disorders

Jáuregui-Lobera I, Bolaños-Ríos P, Ruiz-Prieto I

International Journal of General Medicine 2012, 5:823-830

Published Date: 5 October 2012

Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery

Gao D, Tang S, Tong Q

International Journal of Nanomedicine 2012, 7:3517-3526

Published Date: 6 July 2012

Assessing awareness and knowledge of hypertension in an at-risk population in the Karen ethnic rural community, Thasongyang, Thailand

Aung MN, Lorga T, Srikrajang J, Promtingkran N, Kreuangchai S, Tonpanya W, Vivarakanon P, Jaiin P, Praipaksin N, Payaprom A

International Journal of General Medicine 2012, 5:553-561

Published Date: 27 June 2012

Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder

Gonzalez JM, Thompson PM, Moore TA

Patient Preference and Adherence 2011, 5:333-341

Published Date: 1 July 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009